Lack of evidence for improved β-adrenoceptor-mediated papillary muscle contraction by low-dose empagliflozin treatment in a rat model of streptozotocin-induced diabetes
Abstract
Diabetes mellitus leads to cardiovascular complications including impaired cardiac β-adrenoceptor (β-AR)
function. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin (EMPA), improve outcomes in heart
failure patients and animal models. Therefore, we have investigated the effects of EMPA on in vivo cardiac function and
β-AR mediated contractile responses in streptozotocin (STZ)-induced diabetes in a design reflecting late-onset of
treatment. Male Sprague Dawley rats were divided into 4 groups (control, EMPA-treated control, diabetic, and EMPA-
treated diabetic). Diabetes was induced by STZ injection (40 mg/kg). 13-16 weeks after STZ injection, a low dose of
EMPA (10 mg/kg/day, daily oral gavage) or vehicle was administered for another 8 weeks. At the end of the treatment
period, in vivo cardiac function was evaluated by pressure-volume (PV) loop analysis and β-AR mediated contractile
response was determined by isoprenaline on isolated papillary strips. The blood glucose-lowering effect of low-dose
EMPA was confirmed. EMPA did not change cardiac function in control rats. Diabetic rats had a reduced heart rate,
cardiac output, stroke work, rate of contraction and rate of relaxation and increased isovolumic relaxation, whereas in
vitro responses were not markedly attenuated. Treatment with EMPA showed a trend for improvement of some (e.g.,
stroke volume, ejection fraction, cardiac index) but not all parameters. Our results indicate that low-dose EMPA…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.